Leadership change
Swiss biotech company Anaveon has appointed a new Chief Executive Officer. As the company announced in March, experienced biopharma executive Thaminda Ramanayake will take over the leadership of the Basel-based firm.
Ramanayake brings more than 20 years of global experience in the biopharmaceutical industry. Most recently, he served as Chief Business Officer at mRNA specialist CureVac, where he played a key role in the company’s strategic transformation and its acquisition by BioNTech in 2025. Earlier in his career, he held senior roles at Sanofi, BioMarin, and Amgen, leading business development, partnerships, and major transactions.
Anaveon’s Chairman, Dieter Weinand, described Ramanayake as a “proven leader” with strong strategic expertise, well suited to guide the company into its next phase as it advances its immunology pipeline.
Ramanayake himself emphasized the company’s potential, highlighting its work on precisely controlling T cells to address unmet needs in autoimmune and inflammatory diseases. He pointed in particular to the lead candidate ANV200, which has shown promising data.
Outgoing CEO Andreas Katopodis, who has led Anaveon since its founding, expressed confidence that his successor will successfully drive the company’s continued growth. Chief Science Officer Christoph Huber also underscored the company’s strong scientific foundation.
With the leadership change, Anaveon aims to further strengthen its position in immunology and accelerate the development of new therapies.
Microbiotica
Centauri Therapeutics
lkov - adobe stock photo